Melissa Stevens
Showing 16–18 of 18 transcripts.
- Milken Institute1h 1m
New Wave Giving: How the Next Generation of Philanthropists Is Rethinking the Model
Melissa Stevens, Matt Dalio, Leili Gerami, Justin Rockefeller, Cameron Saul, Darius Baxter
Driven by an estimated $27 trillion wealth transfer and complex global challenges, modern philanthropy is shifting from traditional grant-making toward scalable hybrid models that integrate for-profit mechanisms with social impact goals. Key figures like Matt Dalio, Cameron Saul, and Lely Jarami exemplify this evolution by leveraging supply chains, consumerism, and media platforms to address poverty and access issues while the Rockefeller Brothers Fund and new family office networks prioritize data-driven metrics over anecdotal evidence. This movement emphasizes intergenerational legacy and cross-border collaboration, positioning moral investment and early entrepreneurial engagement as central strategies for solving intractable problems through market-based solutions.
- Milken Institute1h 3m
Chasing Cures: Reinventing the Business of Medicine
Melissa Stevens, John Noseworthy, Francis Collins, Mark Rothera, Melinda Richter, Monsef Slaoui
A panel of industry leaders and NIH officials advocates transforming biomedical research through open innovation models like the Accelerating Medicines Partnership, which pools $30 billion in funding to address major diseases by sharing data across pre-competitive collaborations. The discussion highlights a strategic shift toward patient-centric trials using real-world evidence and wearable technology to accelerate discovery while redefining value to include safety and patient-defined outcomes over mere cost containment. Looking ahead, experts anticipate breakthroughs in bio-electronic medicine and precision therapies, driven by regulatory reforms for orphan drugs and non-traditional partnerships that prioritize patient access over traditional discovery-to-commercialization silos.
- Milken Institute1h 0m
Financing the Future of Bioscience and Pharma
Melissa Stevens, Lou DiGennaro, Rajiv Kahl, Jody Black, Matthew Perry, Greg Simon
Facing a critical funding gap where traditional venture capital and pharmaceutical giants avoid high-risk early-stage assets, diverse entities including the Leukemia & Lymphoma Society, the NIH, and crowdfunding platforms like Poliwag are deploying non-dilutive capital and democratized investment models to accelerate therapeutic development. These initiatives have successfully leveraged millions to generate billions in downstream deal flow, while regulatory shifts and public market mechanisms enable smaller biotechs to bridge the "valley of death" and reach patients faster. Ultimately, the event highlights a structural shift toward a continuum of care where government research, patient advocacy, and public markets converge to transform scientific discovery into viable treatments for life-threatening diseases.